Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study

• Published in: PLoS medicine 2022-05, Vol.19 (5), p.e1003991
• Main Authors: van Gils, Marit J, Lavell, Ayesha, van der Straten, Karlijn, Appelman, Brent, Bontjer, Ilja, Poniman, Meliawati, Burger, Judith A, Oomen, Melissa, Bouhuijs, Joey H, van Vught, Lonneke A, Slim, Marleen A, Schinkel, Michiel, Wynberg, Elke, van Willigen, Hugo D G, Grobben, Marloes, Tejjani, Khadija, van Rijswijk, Jacqueline, Snitselaar, Jonne L, Caniels, Tom G, Vlaar, Alexander P J, Prins, Maria, de Jong, Menno D, de Bree, Godelieve J, Sikkens, Jonne J, Bomers, Marije K, Sanders, Rogier W
• Format: Article
• Language: English
• Subjects: 2019-nCoV Vaccine mRNA-1273; Ad26COVS1; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Antibody Formation; Biology and Life Sciences; BNT162 Vaccine; Cell-mediated immunity; ChAdOx1 nCoV-19; Cohort analysis; Cohort Studies; Comparative analysis; Coronaviruses; COVID-19 - epidemiology; COVID-19 - prevention & control; COVID-19 Vaccines; Drug dosages; Evaluation; Health aspects; Health care; Health Personnel; Hospitalization; Humans; Immunity (cell-mediated); Immunization; Infections; Medical personnel; Medicine and Health Sciences; mRNA; mRNA vaccines; Mutation; Netherlands - epidemiology; Pandemics; Prospective Studies; Proteins; SARS-CoV-2 - genetics; Severe acute respiratory syndrome coronavirus 2; Viral antibodies
• ISSN: 1549-1676; 1549-1277; 1549-1676
• DOI: 10.1371/journal.pmed.1003991

Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of vaccination campaigns. Therefore, it is important to know how the different vaccines perform against diverse SARS-CoV-2 variants. In a prospective cohort of 165 SARS-CoV-2 naive health care workers in the Netherlands, vaccinated with either one of four vaccines (BNT162b2, mRNA-1273, AZD1222 or Ad26.COV2.S), we performed a head-to-head comparison of the ability of sera to recognize and neutralize SARS-CoV-2 variants of concern (VOCs; Alpha, Beta, Gamma, Delta and Omicron). Repeated serum sampling was performed 5 times during a year (from January 2021 till January 2022), including before and after booster vaccination with BNT162b2. Four weeks after completing the initial vaccination series, SARS-CoV-2 wild-type neutralizing antibody titers were highest in recipients of mRNA-1273, followed by recipients of BNT162b2 (geometric mean titers (GMT) of 358 [95% CI 231-556] and 214 [95% CI 153-299], respectively; p